Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesU.s. food and drug administration approves onglyza (saxagliptin) for the treatment of type 2 diabetes mellitus in adults
AstraZeneca, 08/04/09
Bristol–Myers Squibb Company and AstraZeneca announced that the U.S. Food and Drug Administration approved ONGLYZA (saxagliptin), a dipeptidyl peptidase–4 inhibitor. ONGLYZA is indicated as an adjunct to diet and exercise to improve blood sugar control in adults for the treatment of type 2 diabetes mellitus. ONGLYZA once daily can be used in combination with commonly prescribed oral anti–diabetic medications – metformin, sulfonylureas or thiazolidinediones (TZD) – or as a monotherapy to significantly reduce glycosylated hemoglobin levels.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/03/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Does Simvastatin Cause More Myotoxicity Compared with Other Statins
Annals of Pharmacotherapy, 12/03/09
Myxedema Coma Associated with Combination Aripiprazole and Sertraline Therapy
Annals of Pharmacotherapy, 12/03/09
Factors Associated with Multiple Medication Use in Different Age Groups
Annals of Pharmacotherapy, 12/03/09
Sponsor
Article Search
Sponsor